

# **FAMOTIDINE - famotidine powder, for suspension**

## **Aurobindo Pharma Limited**

---

### **HIGHLIGHTS OF PRESCRIBING INFORMATION**

**These highlights do not include all the information needed to use FAMOTIDINE FOR ORAL SUSPENSION safely and effectively. See full prescribing information for FAMOTIDINE FOR ORAL SUSPENSION.**

### **FAMOTIDINE for oral suspension**

**Initial U.S. Approval: 1986**

#### **INDICATIONS AND USAGE**

Famotidine for oral suspension is a histamine-2 (H<sub>2</sub>) receptor antagonist indicated (1):

In adults for the treatment of:

- active duodenal ulcer (DU).
- active gastric ulcer (GU).
- symptomatic nonerosive gastroesophageal reflux disease (GERD).
- erosive esophagitis due to GERD, diagnosed by biopsy.
- treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
- reduction of the risk of DU recurrence.

In pediatric patients 1 year of age and older for the treatment of:

- peptic ulcer.
- GERD with or without esophagitis and ulcerations.

In pediatric patients from birth to less than 1 year of age for the treatment of:

- GERD.

#### **DOSAGE AND ADMINISTRATION**

- Recommended adult dosage by indication (2.1):

|  |   |
|--|---|
| Active DU                              | 40 mg once daily; or<br>20 mg twice daily                                     |
| Active GU                              | 40 mg once daily  |
| Symptomatic Nonerosive GERD            | 20 mg twice daily   |
| Erosive Esophagitis due to GERD        | 20 mg twice daily; or<br>40 mg twice daily                                    |
| Pathological Hypersecretory Conditions | 20 mg every 6 hours; adjust to patient needs;<br>maximum 160 mg every 6 hours |
| Risk Reduction of DU Recurrence        | 20 mg once daily  |

- Recommended pediatric dosage by indication (2.2):

|   |   |
|---|---|
| Peptic Ulcer Disease                                | <u>1 year to less than 17 years</u><br>Starting dosage 0.5 mg/kg once daily; or<br>0.25 mg/kg twice daily; may increase to<br>1 mg/kg once daily at bedtime or 0.5 mg/kg twice daily;<br>Maximum of 40 mg per day |
|   | <u>Birth to less than 3 months</u><br>Starting dosage 0.5 mg/kg once daily;<br>may increase to 1 mg/kg once daily   |
| GERD  | <u>3 months to less than 1 year</u><br>Starting dosage 0.5 mg/kg twice daily;<br>may increase to 1 mg/kg twice daily; Maximum of 40 mg per day  |
|   |   |
| GERD with or without<br>esophagitis and ulcerations | <u>1 year to less than 17 years</u><br>0.5 mg/kg twice daily<br>Maximum of 40 mg twice daily  |
|   |   |

- See full prescribing information for complete dosing information in adults and pediatrics, recommended treatment duration by indication, and dosage adjustment for adult patients with renal impairment. (2.1, 2.2, 2.3)

#### Administration (2.4):

- Take once daily before bedtime or twice daily in the morning and before bedtime with or without food.

#### **DOSAGE FORMS AND STRENGTHS**

For oral suspension: 50 mL after reconstitution (40 mg/5 mL) (3)

#### **CONTRAINDICATIONS**

History of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H<sub>2</sub>-receptor antagonists. (4)

#### **WARNINGS AND PRECAUTIONS**

- Central Nervous System (CNS) Adverse Reactions: Elderly patients and patients with renal impairment at increased risk; reduce the dosage. (2.1, 5.1, 8.5, 8.6)
- GI Malignancy: Absence of GI symptoms does not preclude the presence of gastric malignancy; evaluate prior to initiating therapy. (5.2)

#### **ADVERSE REACTIONS**

The most common adverse reactions are: headache, dizziness, constipation, and diarrhea. (6.1)

**To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

#### **DRUG INTERACTIONS**

- Drugs Dependent on Gastric pH for Absorption: Systemic exposure of the concomitant drug may be significantly reduced leading to loss of efficacy. (7.1)
- Tizanidine (CYP1A2) Substrate: Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible. (7.2)

#### **USE IN SPECIFIC POPULATIONS**

- Geriatric Use: Use the lowest effective dose for an elderly patient and monitor renal function. (2.1, 5.1, 8.5)
- Renal Impairment: Risk of CNS adverse reactions and QT prolongation in patients with moderate and severe renal impairment; reduce the dosage in adults. (2.3, 8.6)

**See 17 for PATIENT COUNSELING INFORMATION.**

**Revised: 9/2024**

---

## **FULL PRESCRIBING INFORMATION: CONTENTS\***

### **1 INDICATIONS AND USAGE**

### **2 DOSAGE AND ADMINISTRATION**

2.1 Recommended Dosage in Adults

2.2 Recommended Dosage in Pediatric Patients

2.3 Recommended Dosage in Adults with Renal Impairment

2.4 Preparation and Administration Instructions

### **3 DOSAGE FORMS AND STRENGTHS**

### **4 CONTRAINDICATIONS**

### **5 WARNINGS AND PRECAUTIONS**

5.1 Central Nervous System Adverse Reactions

5.2 Concurrent Gastric Malignancy

## **6 ADVERSE REACTIONS**

- 6.1 Clinical Trial Experience
- 6.2 Postmarketing Experience

## **7 DRUG INTERACTIONS**

- 7.1 Drugs Dependent on Gastric pH for Absorption
- 7.2 Tizanidine (CYP1A2 Substrate)

## **8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment

## **10 OVERDOSAGE**

## **11 DESCRIPTION**

## **12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

## **13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

## **14 CLINICAL STUDIES**

- 14.1 Active Duodenal Ulcer (DU)
- 14.2 Active Gastric Ulcer (GU)
- 14.3 Symptomatic Gastroesophageal Reflux Disease (GERD)
- 14.4 Erosive Esophagitis Due to GERD
- 14.5 Pathological Hypersecretory Conditions
- 14.6 Risk Reduction of DU Recurrence
- 14.7 GERD in Pediatric Patients Less Than 1 Year of Age

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

## **17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

## **FULL PRESCRIBING INFORMATION**

### **1 INDICATIONS AND USAGE**

Famotidine for oral suspension is indicated in adults for the treatment of:

- active duodenal ulcer (DU).
- active gastric ulcer (GU).
- symptomatic nonerosive gastroesophageal reflux disease (GERD).
- erosive esophagitis due to GERD, diagnosed by biopsy.
- treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
- reduction of the risk of DU recurrence.

Famotidine for oral suspension is indicated in pediatric patients 1 year of age and older for the treatment of:

- peptic ulcer disease.
- GERD with or without esophagitis and ulcerations.

Famotidine for oral suspension is indicated in pediatric patients from birth to less than 1 year of age for the treatment of:

- GERD.

## 2 DOSAGE AND ADMINISTRATION

### 2.1 Recommended Dosage in Adults

The recommended dosage and duration of famotidine for oral suspension in adults with normal renal function is shown in Table 1.

- After preparation, the concentration of famotidine for oral suspension is 8 mg/mL [see *Dosage and Administration* (2.3)].

**Table 1: Recommended Dosage and Duration of Famotidine for Oral Suspension in Adults with Normal Renal Function**

| Indication  | Recommended Dosage  | Recommended Duration                              |
|---|---|---|
| Active DU   | 40 mg once daily; or<br>20 mg twice daily <sup>a</sup>  | Up to 8 weeks <sup>b, c</sup>                     |
| Active GU   | 40 mg once daily  | Up to 8 weeks <sup>c</sup>                        |
| Symptomatic nonerosive GERD                             | 20 mg twice daily   | Up to 6 weeks <sup>c</sup>                        |
| Erosive esophagitis due to GERD, diagnosed by endoscopy | 20 mg twice daily; or<br>40 mg twice daily <sup>a</sup>   | Up to 12 weeks                                    |
| Pathological hypersecretory conditions                  | Starting dosage: 20 mg every 6 hours;<br>adjust dosage to individual patient needs<br>Maximum dosage 160 mg every 6 hours | As clinically indicated                           |
| Reduction of the risk of DU recurrence                  | 20 mg once daily  | 1 year <sup>b, c</sup> or as clinically indicated |

<sup>a</sup> Both dosages demonstrated effectiveness in clinical trials [see *Clinical Studies* (14)].

<sup>b</sup> In clinical trials, the majority of patients healed within 4 weeks. For patients who do not heal after 4 weeks, consider an additional 2 to 4 weeks of treatment [see *Clinical Studies* (14.1)].

<sup>c</sup> Longer treatment durations have not been studied in clinical trials [see *Clinical Studies* (14.1, 14.2, 14.3)].

### 2.2 Recommended Dosage in Pediatric Patients

The recommended dosage and duration of famotidine for oral suspension in pediatric patients with normal renal function is shown in Table 2.

- After preparation, the concentration of famotidine for oral suspension is 8 mg/mL [see *Dosage and Administration* (2.3)].

**Table 2: Recommended Dosage and Duration of Famotidine for Oral Suspension in Pediatric Patients with Normal Renal Function**

| <b>Indication</b>                                | <b>Pediatric Age Range</b>   | <b>Recommended Dosage</b>   | <b>Duration</b>                |
|--|------------------------------|---|--------------------------------|
| Peptic Ulcer Disease                             | 1 year to less than 17 years | Starting dosage 0.5 mg/kg once daily; or 0.25 mg/kg twice daily<br><br>May increase to 1 mg/kg once daily at bedtime or 0.5 mg/kg twice daily<br><br>Maximum of 40 mg per day | 8 weeks <sup>a</sup>           |
| GERD   | Birth to less than 3 months  | Starting dosage 0.5 mg/kg once daily.<br><br>May increase to 1 mg/kg once daily <sup>a</sup>  | Up to 8 weeks <sup>a,b,c</sup> |
|  | 3 months to less than 1 year | Starting dosage 0.5 mg/kg twice daily. May increase to 1 mg/kg twice daily <sup>b</sup><br><br>Maximum of 40 mg per day   |                                |
| GERD with or without esophagitis and ulcerations | 1 year to less than 17 years | 0.5 mg/kg twice daily<br><br>Maximum of 40 mg twice daily   | 6 to 12 weeks <sup>a</sup>     |

<sup>a</sup> Treatment duration based on adult recommendations (see Table 1). Individualize the dose and duration based upon clinical response and/or pH determinations (gastric or esophageal) and endoscopy.

<sup>b</sup> Use conservative measures (e.g., thickened feedings) concurrently [see *Use in Specific Populations* (8.4)].

<sup>c</sup> After 4 weeks of treatment re-evaluate the patient. Consider an additional 4 weeks of treatment if treatment benefit outweighs potential risks.

## 2.3 Recommended Dosage in Adults with Renal Impairment

Recommended dosage adjustments for adults with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) by indication are shown in Table 3. Use the lowest effective dosage [see *Use in Specific Populations* (8.6)].

A safe and effective dosage has not been established in pediatric patients with renal impairment.

**Table 3: Recommended Maximum Dosage of Famotidine for Oral Suspension in Adults with Moderate and Severe Renal Impairment**

| <b>Indication</b>   | <b>Recommended Maximum Dosage</b>                          |  |
|---|--|--|
|   | <b>Creatinine Clearance<br/>30 to 60 mL/minute</b>         | <b>Creatinine Clearance<br/>Less Than 30<br/>mL/minute</b> |
| Active DU   | 20 mg once daily; or<br>40 mg every other day              | 10 mg once daily; or<br>20 mg every other day              |
| Active GU   | 20 mg once daily; or<br>40 mg every other day              | 10 mg once daily; or<br>20 mg every other day              |
| Symptomatic nonerosive GERD   | 20 mg once daily   | 10 mg once daily; or<br>20 mg every other day              |
| Erosive esophagitis due to GERD,<br>diagnosed by endoscopy <sup>a</sup> | 20 mg once daily; or<br>40 mg every other day <sup>b</sup> | 10 mg once daily; or<br>20 mg every other day <sup>b</sup> |
| Pathological hypersecretory conditions                                  |  | Avoid use <sup>b</sup>                                     |
| Reduction of the risk of DU recurrence                                  | 10 mg once daily; or<br>20 mg every other day              | 10 mg every other day                                      |

<sup>a</sup> Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials [see *Clinical Studies (14.4)*].

<sup>b</sup> The dosage required to treat pathological hypersecretory conditions may exceed the maximum dosage evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with famotidine for oral suspension for pathological hypersecretory conditions is unknown.

## 2.4 Preparation and Administration Instructions

### Preparation of Reconstituted Suspension by a Healthcare Provider Prior to Dispensing

- Prior to dispensing, constitute famotidine for oral suspension by slowly adding 46 mL of purified water to the bottle.
- Shake vigorously for 5 to 10 seconds immediately after adding the water.
- The bottle of constituted suspension contains 50 mL (40 mg of famotidine per 5 mL), and should be a white to off-white flavoured homogenous suspension.

### Administration and Storage of Constituted Suspension

- Shake the bottle of constituted famotidine for oral suspension vigorously for 5 to 10 seconds prior to each use.
- Take famotidine for oral suspension once daily before bedtime or twice daily in the morning and before bedtime, as recommended.
- Famotidine for oral suspension may be taken with or without food [see *Clinical Pharmacology (12.3)*].
- Famotidine for oral suspension may be given with antacids.
- Store the constituted suspension at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from freezing. Discard unused constituted suspension after 30 days.

## **3 DOSAGE FORMS AND STRENGTHS**

For Oral Suspension: 400 mg as a white to off-white granular powder. When constituted as directed, famotidine for oral suspension, USP is a white to off-white flavoured homogenous suspension containing 50 mL after reconstitution (40 mg of famotidine, USP per 5 mL).

## **4 CONTRAINDICATIONS**

Famotidine for oral suspension is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis) to famotidine or other H<sub>2</sub>-receptor antagonists.

## **5 WARNINGS AND PRECAUTIONS**

### **5.1 Central Nervous System Adverse Reactions**

Central nervous system (CNS) adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy, have been reported in elderly patients and patients with moderate and severe renal impairment treated with famotidine. Since famotidine blood levels are higher in patients with renal impairment than in patients with normal renal function, dosage adjustments are recommended in patients with renal impairment [*see Dosage and Administration (2.2), Clinical Pharmacology (12.3)*].

### **5.2 Concurrent Gastric Malignancy**

In adults, symptomatic response to therapy with famotidine for oral suspension does not preclude the presence of gastric malignancy. Consider evaluation for gastric malignancy in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with famotidine for oral suspension.

## **6 ADVERSE REACTIONS**

### **6.1 Clinical Trial Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of famotidine for oral suspension has been established based on adequate and well-controlled studies of another oral famotidine product [*see Clinical Studies (14)*]. The following is a summary of the adverse reactions reported in those studies.

Oral famotidine was studied in 7 U.S. and international placebo- and active-controlled trials in approximately 2500 patients [*see Clinical Studies (14)*]. A total of 1442 patients were treated with famotidine, including 302 treated with 40 mg twice daily, 456 treated with 20 mg twice daily, 461 treated with 40 mg once daily, and 396 treated with 20 mg once daily. The population was 17 to 91 years old, fairly well distributed between sex and

race; however, the predominant race was White.

The following adverse reactions occurred in greater than or equal to 1% of famotidine-treated patients: headache, dizziness and constipation.

The following other adverse reactions were reported in less than 1% of patients in clinical trials:

*Body as a Whole:* fever, asthenia, fatigue

*Cardiovascular:* palpitations

*Gastrointestinal:* elevated liver enzymes, vomiting, nausea, abdominal discomfort, anorexia, dry mouth

*Hematologic:* thrombocytopenia

*Hypersensitivity:* orbital edema, rash, conjunctival injection, bronchospasm

*Musculoskeletal:* musculoskeletal pain, arthralgia

*Nervous System/Psychiatric:* seizure, hallucinations, depression, anxiety, decreased libido, insomnia, somnolence

*Skin:* pruritus, dry skin, flushing

*Special Senses:* tinnitus, taste disorder

*Other:* impotence

#### Pediatric Patients Less Than 1 Year of Age

In a clinical study in 35 pediatric patients less than 1 year of age with GERD symptoms, two patients discontinued due to adverse reactions. Agitation observed in 5 patients resolved when famotidine was discontinued [see *Use in Specific Populations (8.4)*].

## **6.2 Postmarketing Experience**

The following adverse reactions have been identified during post-approval use of famotidine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Cardiovascular:* arrhythmia, AV block, prolonged QT interval

*Gastrointestinal:* cholestatic jaundice, hepatitis

*Hematologic:* agranulocytosis, pancytopenia, leukopenia

*Hypersensitivity:* anaphylaxis, angioedema, facial edema, urticaria

*Musculoskeletal:* rhabdomyolysis, muscle cramps

*Nervous System/Psychiatric:* confusion, agitation, paresthesia

*Respiratory:* interstitial pneumonia

*Skin:* toxic epidermal necrolysis/Stevens-Johnson syndrome

## 7 DRUG INTERACTIONS

### 7.1 Drugs Dependent on Gastric pH for Absorption

Famotidine can reduce the absorption of other drugs due to its effect on reducing intragastric acidity, leading to loss of efficacy of the concomitant drug.

Concomitant administration of famotidine for oral suspension with dasatinib, delavirdine mesylate, cedifitoren, and fosamprenavir is not recommended.

See the prescribing information for other drugs dependent on gastric pH for absorption for administration instructions, including atazanavir, erlotinib, ketoconazole, itraconazole, ledipasvir/sofosbuvir, nilotinib, and rilpivirine.

### 7.2 Tizanidine (CYP1A2 Substrate)

Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Avoid concomitant use with famotidine for oral suspension. If concomitant use is necessary, monitor for hypotension, bradycardia or excessive drowsiness. Refer to the full prescribing information for tizanidine.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

Available data with H<sub>2</sub>-receptor antagonists, including famotidine, in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse development effects were observed with oral administration of famotidine at doses up to approximately 243 and 122 times, respectively, the recommended human dose of 80 mg/day for the treatment of erosive esophagitis (see *Data*).

The estimated background risk for major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

#### Data

##### *Animal Data*

Reproductive studies have been performed in rats and rabbits at oral doses of up to

2000 and 500 mg/kg/day, respectively, and in both species at intravenous doses of up to 200 mg/kg/day, and have revealed no significant evidence of impaired fertility or harm to the fetus due to famotidine. While no direct fetotoxic effects have been observed, sporadic abortions occurring only in mothers displaying marked decreased food intake were seen in some rabbits at oral doses of 200 mg/kg/day (about 49 times the recommended human dose of 80 mg/day, based on body surface area) or higher. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

## **8.2 Lactation**

### Risk Summary

There are limited data available on the presence of famotidine in human breast milk. There were no effects on the breastfed infant. There are no data on famotidine effects on milk production. Famotidine is present in the milk of lactating rats (see *Data*).

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for famotidine and any potential adverse effects on the breastfed child from famotidine for oral suspension or from the underlying maternal condition.

### Data

#### *Animal Data*

Transient growth depression was observed in young rats suckling from mother's treated with maternotoxic doses of famotidine at least 600 times the usual human dose.

## **8.4 Pediatric Use**

### Peptic Ulcer Disease and GERD With or Without Esophagitis and Ulcerations

#### *Pediatric Patients 1 Year to Less Than 17 Years of Age*

The safety and effectiveness of famotidine for oral suspension have been established in pediatric patients 1 year to less than 17 years of age for the treatment of peptic ulcer disease and GERD with or without esophagitis and ulcerations. Use of famotidine for oral suspension in this age group is supported by evidence from adequate and well-controlled studies of famotidine in adults with additional pharmacokinetic and pharmacodynamic data in pediatric patients 1 year to less than 17 years of age [see *Dosage and Administration* (2.2), *Clinical Pharmacology* (12.2, 12.3)]. The safety and effectiveness of famotidine for oral suspension for the treatment of peptic ulcer disease in pediatric patients less than 1 year of age have not been established.

### GERD

## Pediatric Patients Less Than 1 Year of Age

The safety and effectiveness of famotidine for oral suspension have been established in pediatric patients from birth to less than 1 year of age for the treatment of GERD. The use of famotidine for oral suspension in this age group is supported by evidence from adequate and well-controlled studies of famotidine in adults and with supportive data in pediatric patients from birth to less than 1 year of age [see *Dosage and Administration* (2.2), *Clinical Pharmacology* (12.2, 12.3), *Clinical Studies* (14.7)].

## Other Conditions

The safety and effectiveness for the treatment of pathological hypersecretory conditions and reduction of risk of DU recurrence have not been established in pediatric patients.

A safe and effective dosage has not been established in pediatric patients with renal impairment.

## **8.5 Geriatric Use**

Of the 1442 famotidine-treated patients in clinical studies, approximately 10% were 65 and older. In these studies, no overall differences in safety or effectiveness were observed between elderly and younger patients. In postmarketing experience, CNS adverse reactions have been reported in elderly patients with and without renal impairment receiving famotidine [see *Warnings and Precautions* (5.1)].

Famotidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to famotidine for oral suspension may be greater in elderly patients, particularly those with impaired renal function [see *Use in Specific Populations* (8.6)].

In general, use the lowest effective dose of famotidine for oral suspension for an elderly patient and monitor renal function [see *Dosage and Administration* (2.2)].

## **8.6 Renal Impairment**

CNS adverse reactions and prolonged QT intervals have been reported in patients with moderate and severe renal impairment [see *Warnings and Precautions* (5.1)]. The clearance of famotidine is reduced in adults with moderate and severe renal impairment compared to adults with normal renal function [see *Clinical Pharmacology* (12.3)]. No dosage adjustment is needed in adults with mild renal impairment (creatinine clearance greater than or equal to 60 mL/min). Dosage reduction is recommended in adults with moderate or severe renal impairment (creatinine clearance less than 60 mL/min) [see *Dosage and Administration* (2.3)]. Data are not available to establish a safe and effective dosage in pediatric patients with renal impairment.

## **10 OVERDOSAGE**

The types of adverse reactions in overdosage of famotidine are similar to the adverse reactions encountered with use of recommended dosages [see *Adverse Reactions*


(6.1)].

In the event of overdosage, treatment should be symptomatic and supportive. Unabsorbed material should be removed from the gastrointestinal tract, the patient should be monitored, and supportive therapy should be employed.

Due to low binding to plasma proteins, famotidine is eliminated by hemodialysis. There is limited experience on the usefulness of hemodialysis as a treatment for famotidine overdosage.

## 11 DESCRIPTION

The active ingredient in famotidine for oral suspension, USP is a H<sub>2</sub>-receptor antagonist. Famotidine is *N'*-(aminosulfonyl)-3-[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide. The molecular formula of famotidine is C<sub>8</sub>H<sub>15</sub>N<sub>7</sub>O<sub>2</sub>S<sub>3</sub> and its molecular weight is 337.43. Its structural formula is:



Each 5 mL of famotidine for oral suspension, USP when prepared as directed contains 40 mg of famotidine, USP and the following inactive ingredients: banana flavor (contains propylene glycol), cherry flavor (contains acetic acid, propylene glycol and triethyl citrate), citric acid monohydrate, peppermint flavor (contains ethyl alcohol and water), powdered cellulose, sucrose and xanthan gum. Added as preservatives are methylparaben sodium 0.1%, propylparaben sodium 0.02% and sodium benzoate 0.1%.

Each 5 mL of famotidine for oral suspension USP contains 2 mg of sodium.

Famotidine, USP is a white to pale yellowish white crystalline powder that is freely soluble in dimethyl formamide, glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, practically insoluble in acetone, in alcohol, in chloroform, in ether and in ethyl acetate.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Famotidine is a competitive inhibitor of H<sub>2</sub>-receptors. The primary clinically important

pharmacologic activity of famotidine is inhibition of gastric secretion. Both the acid concentration and volume of gastric secretion are suppressed by famotidine, while changes in pepsin secretion are proportional to volume output.

## 12.2 Pharmacodynamics

### Adults

Famotidine inhibited both basal and nocturnal gastric secretion, as well as secretion stimulated by food and pentagastrin. After oral administration of famotidine, the onset of the antisecretory effect occurred within 1 hour; the maximum effect was dose-dependent, occurring within 1 to 3 hours. Duration of inhibition of secretion by doses of 20 mg and 40 mg was 10 to 12 hours.

Single evening oral doses of 20 mg and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours. The same doses given in the morning suppressed food-stimulated acid secretion in all subjects. The mean suppression was 76% and 84%, respectively, 3 to 5 hours after administration, and 25% and 30%, respectively, 8 to 10 hours after administration. In some subjects who received the 20 mg dose, however, the antisecretory effect was dissipated within 6 to 8 hours. There was no cumulative effect with repeated doses. The nocturnal intragastric pH was raised by evening doses of 20 mg and 40 mg of famotidine to mean values of 5.0 and 6.4, respectively. When famotidine was given after breakfast, the basal daytime interdigestive pH at 3 and 8 hours after 20 mg or 40 mg of famotidine was raised to a pH level of about 5.

Famotidine had little or no effect on fasting or postprandial serum gastrin levels. Gastric emptying and exocrine pancreatic function were not affected by famotidine.

In clinical pharmacology studies, systemic effects of famotidine in the CNS, cardiovascular, respiratory or endocrine systems were not noted. Also, no anti-androgenic effects were noted. Serum hormone levels, including prolactin, cortisol, thyroxine (T<sub>4</sub>), and testosterone, were not altered after treatment with famotidine.

### Pediatric Patients

Pharmacodynamics of famotidine, assessed by gastric pH, were evaluated in 5 pediatric patients 2 years to 13 years of age using the sigmoid E<sub>max</sub> model. These data suggest that the relationship between serum concentration of famotidine and gastric acid suppression is similar to that observed in adults (see Table 4).

**Table 4: Serum Concentrations of Famotidine Associated with Gastric Acid Reduction in Famotidine-Treated Pediatric and Adult Patients<sup>a</sup>**

|                    | <b>EC<sub>50</sub>(ng/mL)<sup>a</sup></b> |
|--------------------|---|
| Pediatric Patients | 26 ± 13                                   |

| Adults                                |             |
|---------------------------------------|-------------|
| Healthy adult subjects                | 26.5 ± 10.3 |
| Adult patients with upper GI bleeding | 18.7 ± 10.8 |

<sup>a</sup> Using the sigmoid E<sub>max</sub> model, serum concentrations of famotidine associated with 50% maximum gastric acid reduction are presented as mean ± SD.

In a study examining the effect of famotidine on gastric pH and duration of acid suppression in pediatric patients, four pediatric patients ages 11 to 15 years of age using the oral formulation at a dose of 0.5 mg/kg, maintained a gastric pH above 5 for 13.5 ± 1.8 hours.

## 12.3 Pharmacokinetics

### Absorption

Famotidine is incompletely absorbed. The bioavailability of oral doses is 40 to 45%. Bioavailability may be slightly increased by food, or slightly decreased by antacids; however, these effects are of no clinical consequence.

Peak famotidine plasma levels occur in 1 to 3 hours. Plasma levels after multiple dosages are similar to those after single doses.

### Distribution

Fifteen to 20% of famotidine in plasma is protein bound.

### Elimination

#### *Metabolism*

Famotidine undergoes minimal first-pass metabolism. Twenty-five to 30% of an oral dose was recovered in the urine as unchanged compound. The only metabolite identified in humans is the S-oxide.

#### *Excretion*

Famotidine has an elimination half-life of 2.5 to 3.5 hours. Famotidine is eliminated by renal (65 to 70%) and metabolic (30 to 35%) routes. Renal clearance is 250 to 450 mL/min, indicating some tubular excretion.

### Specific Populations

#### *Pediatric Patients*

#### *Infants from Birth to 12 Months*

After a single oral dose administration of 0.5 mg/kg orally in patients from birth to 12 months, the bioavailability is approximately 42%.

The AUC increased 1.4-fold after single oral dose of 1 mg/kg compared to 0.5 mg/kg and 2.7-fold after multiple oral doses of 1 mg/kg compared to 0.5 mg/kg.

Plasma clearance is reduced and elimination half-life is prolonged in pediatric patients from birth to 3 months of age compared to older pediatric patients. Following intravenous administration of 0.5 mg/kg, CLTotal was  $0.13 \pm 0.06$  L/hr/kg,  $0.21 \pm 0.06$  L/hr/kg, and  $0.49 \pm 0.17$  L/hr/kg in pediatric patients <1 month of age, <3 months of age, and >3 to 12 months of age, respectively. Elimination half-life was 10.5 hours, 8.1 hours, and 4.5 hours in pediatric patients <1 month of age, <3 months of age, and >3 to 12 months of age, respectively.

#### *Patients 11 Years to 15 Years*

The mean bioavailability in 8 pediatric patients was 50% compared to adult values of 42% to 49%.

Pharmacokinetic parameters in pediatric patients 11 years to 15 years is compared to infants from birth to 12 months in Table 5.

**Table 5: Mean Pharmacokinetic Parameters Following a Single Oral Dose of 0.5 mg/kg in Infants and Pediatric Patients**

|  | <b>Infants<br/>from Birth to 12<br/>Months<br/>(N=5)</b> | <b>Pediatric Patients<br/>11 Years to 15 Years<br/>(N=8)</b> |
|--|--|--|
| AUC <sub>0-∞</sub> (ng*hr/mL) <sup>a</sup> | $645 \pm 249$  | $580 \pm 60$   |
| C <sub>max</sub> (ng/mL)                   | 79.2   | 97.3   |
| T <sub>max</sub> (hr) <sup>b</sup>         | 2.0 (1.0, 4.1) <sup>c</sup>                              | 2.3 (2.1, 2.9) <sup>d</sup>                                  |
| T <sub>1/2</sub> (hr)                      | 5.82   | 2.13   |

<sup>a</sup> arithmetic mean  $\pm$  S.D.

<sup>b</sup> median

<sup>c</sup> observed minimum and maximum values

<sup>d</sup> reported minimum and maximum values

#### *Patients with Renal Impairment*

In adult patients with severe renal impairment (creatinine clearance less than 30 mL/min), the systemic exposure (AUC) of famotidine increased at least 5-fold. In adult patients with moderate renal impairment (creatinine clearance between 30 to 60 mL/min), the AUC of famotidine increased at least 2-fold [see *Dosage and Administration* (2.3), *Use in Specific Populations* (8.6)].

#### *Drug Interaction Studies*

## *Human Organic Anion Transporter (OAT) 1 and 3*

*In vitro* studies indicate that famotidine is a substrate for OAT1 and OAT3. Following coadministration of probenecid (1500 mg), an inhibitor of OAT1 and OAT3, with a single oral 20 mg dose of famotidine in 8 healthy subjects, the serum AUC<sub>0-10h</sub> of famotidine increased from 424 to 768 ng·hr/mL and the maximum serum concentration (C<sub>max</sub>) increased from 73 to 113 ng/mL. Renal clearance, urinary excretion rate and amount of famotidine excreted unchanged in urine were decreased. The clinical relevance of this interaction is unknown.

## *Multidrug and Toxin Extrusion Protein 1 (MATE-1)*

An *in vitro* study showed that famotidine is an inhibitor of MATE-1. However, no clinically significant interaction with metformin, a substrate for MATE-1, was observed.

## **CYP1A2**

Famotidine is a weak CYP1A2 inhibitor.

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

Carcinogenic potential of famotidine was assessed in a 106-week oral carcinogenicity study in rats and a 92-week oral carcinogenicity study in mice. In the 106-week study in rats and the 92-week study in mice at oral doses of up to 2000 mg/kg/day (approximately 243 and 122 times, respectively, based on body surface area, the recommended human dose of 80 mg/day for the treatment of erosive esophagitis), there was no evidence of carcinogenic potential for famotidine.

Famotidine was negative in the microbial mutagen test (Ames test) using *Salmonella typhimurium* and *Escherichia coli* with or without rat liver enzyme activation at concentrations up to 10,000 mcg/plate. In *in vivo* studies in mice, with a micronucleus test and a chromosomal aberration test, no evidence of a mutagenic effect was observed.

In studies with rats given oral doses of up to 2000 mg/kg/day (approximately 243 times, based on body surface area, the recommended human dose of 80 mg/day) fertility and reproductive performance were not affected.

## **14 CLINICAL STUDIES**

The safety and effectiveness of famotidine for oral suspension have been established based on adequate and well-controlled studies of another oral famotidine product. The following is a summary of the efficacy results reported in those studies.

### **14.1 Active Duodenal Ulcer (DU)**

In a U.S. multicenter, double-blind trial in adult outpatients with endoscopically confirmed duodenal ulcer (DU), orally administered famotidine was compared to placebo. As shown

in Table 6, 70% of patients treated with famotidine 40 mg at bedtime were healed by Week 4. Most patients' DU healed within 4 weeks.

Patients not healed by Week 4 were continued in the trial. By Week 8, 83% of patients treated with famotidine had healed DU, compared to 45% of patients treated with placebo. The incidence of DU healing with famotidine was greater than with placebo at each time point based on proportion of endoscopically confirmed healed DUs. Trials have not assessed the safety of famotidine in uncomplicated active DU for periods of more than 8 weeks.

**Table 6: Patients with Endoscopically Confirmed Healed Duodenal Ulcers**

|        | <b>Famotidine<br/>40 mg at bedtime<br/>(N=89)</b> | <b>Famotidine<br/>20 mg twice daily<br/>(N=84)</b> | <b>Placebo<br/>at bedtime<br/>(N=97)</b> |
|--------|---|--|--|
| Week 2 | 32% <sup>a</sup>                                  | 38% <sup>a</sup>                                   | 17%                                      |
| Week 4 | 70% <sup>a</sup>                                  | 67% <sup>a</sup>                                   | 31%                                      |

<sup>a</sup> p<0.001 vs. placebo

In this study, time to relief of daytime and nocturnal pain was shorter for patients receiving famotidine than for patients receiving placebo; patients receiving famotidine also took less antacid than patients receiving placebo.

#### **14.2 Active Gastric Ulcer (GU)**

In both a U.S. and an international multicenter, double-blind trials in patients with endoscopically confirmed active GU, orally administered famotidine 40 mg at bedtime was compared to placebo. Antacids were permitted during the trials, but consumption was not significantly different between the famotidine and placebo groups.

As shown in Table 7, the incidence of GU healing confirmed by endoscopy (dropouts counted as unhealed) with famotidine was greater than placebo at Weeks 6 and 8 in the U.S. trial, and at Weeks 4, 6 and 8 in the international trial.

In these trials, most famotidine-treated patients healed within 6 weeks. Trials have not assessed the safety of famotidine in uncomplicated active GU for periods of more than 8 weeks.

**Table 7: Patients with Endoscopically Confirmed Healed Gastric Ulcers**

|        | <b>U.S. Study (N=149)</b>                             |  | <b>International Study (N=294)</b>                     |   |
|--------|---|--|--|---|
|        | <b>Famotidine<br/>40 mg at<br/>bedtime<br/>(N=74)</b> | <b>Placebo<br/>at bedtime<br/>(N=75)</b> | <b>Famotidine<br/>40 mg at<br/>bedtime<br/>(N=149)</b> | <b>Placebo<br/>at bedtime<br/>(N=145)</b> |
| Week 4 | 45%   | 39%                                      | 47% <sup>a</sup>                                       | 31%                                       |
| Week 6 | 66% <sup>a</sup>                                      | 44%                                      | 65% <sup>a</sup>                                       | 46%                                       |
| Week 8 | 78% <sup>b</sup>                                      | 64%                                      | 80% <sup>a</sup>                                       | 54%                                       |

<sup>a</sup> p<0.01 vs. placebo

<sup>b</sup> p≤0.05 vs. placebo

Time to complete relief of daytime and nighttime pain was statistically significantly shorter for patients receiving famotidine than for patients receiving placebo; however, neither trial demonstrated a statistically significant difference in the proportion of patients whose pain was relieved by the end of the trial (Week 8).

### 14.3 Symptomatic Gastroesophageal Reflux Disease (GERD)

Orally administered famotidine was compared to placebo in a U.S. trial that enrolled patients with symptoms of GERD and without endoscopic evidence of esophageal erosion or ulceration. As shown in Table 8, patients treated with famotidine 20 mg twice daily had greater improvement in symptomatic GERD than patients treated with 40 mg at bedtime or placebo.

**Table 8: Patients with Improvement of Symptomatic GERD (N=376)**

|        | <b>Famotidine<br/>20 mg twice daily<br/>(N=154)</b> | <b>Famotidine<br/>40 mg at bedtime<br/>(N=149)</b> | <b>Placebo<br/>at bedtime<br/>(N=73)</b> |
|--------|---|--|--|
| Week 6 | 82% <sup>a</sup>                                    | 69%  | 62%                                      |

<sup>a</sup> p≤0.01 vs. placebo

### 14.4 Erosive Esophagitis Due to GERD

Healing of endoscopically verified erosion and symptomatic improvement were studied in a U.S. and an international double-blind trial. Healing was defined as complete resolution of all erosions visible with endoscopy. The U.S. trial comparing orally administered famotidine 40 mg twice daily to placebo and orally administered famotidine 20 mg twice daily showed a significantly greater percentage of healing of erosive esophagitis for famotidine 40 mg twice daily at Weeks 6 and 12 (Table 9).

**Table 9: Patients with Endoscopic Healing of Erosive Esophagitis - U.S. Study (N=318)**

|         | <b>Famotidine<br/>40 mg twice daily<br/>(N=127)</b> | <b>Famotidine<br/>20 mg twice daily<br/>(N=125)</b> | <b>Placebo<br/>twice daily<br/>(N=66)</b> |
|---------|---|---|---|
| Week 6  | 48% <sup>a,b</sup>                                  | 32%   | 18%                                       |
| Week 12 | 69% <sup>a,c</sup>                                  | 54% <sup>a</sup>                                    | 29%                                       |

<sup>a</sup> p≤0.01 vs. placebo

<sup>b</sup> p≤0.01 vs. famotidine 20 mg twice daily

<sup>c</sup> p≤0.05 vs. famotidine 20 mg twice daily

As compared to placebo, patients in the U.S. trial who received famotidine had faster relief of daytime and nighttime heartburn, and a greater percentage of famotidine-treated patients experienced complete relief of nighttime heartburn. These differences were statistically significant.

In the international trial, when orally administered famotidine 40 mg twice daily was compared to orally administered ranitidine 150 mg twice daily, a statistically significantly greater percentage of healing of erosive esophagitis was observed with famotidine 40 mg twice daily at Week 12 (Table 10). There was, however, no significant difference in symptom relief among treatment groups.

**Table 10: Patients with Endoscopic Healing of Erosive Esophagitis - International Study (N=440)**

|         | <b>Famotidine<br/>40 mg twice daily<br/>(N=175)</b> | <b>Famotidine<br/>20 mg twice daily<br/>(N=93)</b> | <b>Ranitidine<br/>150 mg twice<br/>daily<br/>(N=172)</b> |
|---------|---|--|--|
| Week 6  | 48%   | 52%  | 42%  |
| Week 12 | 71% <sup>a</sup>                                    | 68%  | 60%  |

<sup>a</sup> p≤0.05 vs ranitidine 150 mg twice daily

#### **14.5 Pathological Hypersecretory Conditions**

In trials of patients with pathological hypersecretory conditions such as Zollinger-Ellison syndrome with or without multiple endocrine neoplasias, famotidine significantly inhibited gastric acid secretion and controlled associated symptoms. Orally administered famotidine dosages from 20 mg to 160 mg every 6 hours maintained basal acid secretion below 10 mEq/hr; initial dosages were titrated to the individual patient need and subsequent adjustments were necessary with time in some patients.

#### **14.6 Risk Reduction of DU Recurrence**

Two randomized, double-blind, multicenter trials in patients with endoscopically confirmed healed DUs demonstrated that patients receiving treatment with orally administered famotidine 20 mg at bedtime had lower rates of DU recurrence, as compared with placebo:

- In the U.S. trial, DU recurrence within 12 months was 2.4 times greater in patients treated with placebo than in the patients treated with famotidine. The 89 famotidine-treated patients had a cumulative observed DU recurrence rate of 23%, compared to a 57% in the 89 patients receiving placebo (p<0.01).
- In the international trial, the cumulative observed DU recurrence within 12 months in the 307 famotidine-treated patients was 36%, compared to 76% in the 325 patients who received placebo (p<0.01).

Controlled trials have not extended beyond 1 year.

#### **14.7 GERD in Pediatric Patients Less Than 1 Year of Age**

In a double-blind, randomized, treatment-withdrawal study, 35 pediatric patients less than 1 year of age who were diagnosed with GERD, primarily by history of vomiting (spitting up) and irritability (fussiness), were treated for up to 4 weeks with famotidine for oral suspension 0.5 mg/kg or 1 mg/kg administered once daily for patients less than 3 months of age and administered twice daily for patients 3 months to less than 12 months of age. Caregivers were instructed to provide conservative treatment including thickened feedings. After 4 weeks of treatment, patients were randomly withdrawn from the treatment and followed an additional 4 weeks for vomiting (spitting up), irritability (fussiness) and global assessments of improvement. The study patients ranged in age at entry from 1.3 to 10.5 months (mean  $5.6 \pm 2.9$  months), 57% were female, 91% were white and 6% were black. Most patients (27/35) continued into the treatment-withdrawal phase of the study. Most patients improved during the initial treatment phase of the study. Results of the treatment-withdrawal phase were difficult to interpret because of small numbers of patients.

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

Famotidine for oral suspension, USP is supplied as follows:

| <b>NDC</b>   | <b>Strength</b> | <b>Quantity</b> | <b>Description</b>   |
|--------------|-----------------|-----------------|--|
| 59651-701-50 | 40 mg/5 mL      | Bottle          | White to off-white granular powder. When constituted as directed, famotidine for oral suspension, USP is a white to off-white flavoured homogenous suspension containing 50 mL after reconstitution (40 mg of famotidine, USP per 5 mL). |

Prior to dispensing, constitute famotidine for oral suspension, USP [see *Dosage and Administration (2.4)*].

### Storage

Store famotidine for oral suspension, USP dry powder at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Dispense in a USP tight, light-resistant container.

## **17 PATIENT COUNSELING INFORMATION**

### Central Nervous System (CNS) Adverse Reactions

Advise elderly patients and those with moderate and severe renal impairment of the risk of CNS adverse reactions, including confusion, delirium, hallucinations, disorientation, agitation, seizures, and lethargy [see *Warnings and Precautions (5.1)*]. Report symptoms immediately to a healthcare provider.

## QT Interval Prolongation

Advise patients with moderate and severe renal impairment of the risk of QT interval prolongation [see *Use in Specific Populations (8.6)*]. Report new cardiac symptoms, such as palpitations, fainting and dizziness or lightheadedness, immediately to a healthcare provider.

### Administration

- Advise patients to take and caregivers to administer famotidine for oral suspension using an oral dosing syringe to correctly measure the prescribed amount of medication. Oral dosing syringes may be obtained from the pharmacy.
- Shake the bottle of reconstituted famotidine for oral suspension vigorously for 5 to 10 seconds prior to each use.
- Take once daily before bedtime or twice daily in the morning and before bedtime, as recommended, with or without food.
- May be given with antacids.

Distributed by:

**Aurobindo Pharma USA, Inc.**  
279 Princeton-Hightstown Road  
East Windsor, NJ 08520

Manufactured by:

**Aurobindo Pharma Limited**  
Hyderabad-500 032, India

Issued: September 2024

### **PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 40 mg/5 mL (50 mL Bottle)**

**NDC 59651-701-50**

**Rx only**

**Famotidine for  
Oral Suspension, USP  
40 mg/5 mL**

Each 5 mL reconstituted suspension  
contains 40 mg of famotidine.

**SHAKE WELL BEFORE  
EACH USE**

Pharmacist: Must reconstitute before  
dispensing

**AUROBINDO****50 mL  
(after reconstitution)**

NDC 59651-701-50

Rx only

**Famotidine for  
Oral Suspension, USP****40 mg/5 mL**Each 5 mL of reconstituted suspension  
contains 40 mg of famotidine.**SHAKE WELL BEFORE  
EACH USE**Pharmacist: Must reconstitute before  
dispensing

50 mL

(after reconstitution)

**Recommended Dosage:** see Prescribing Information.**DIRECTIONS FOR RECONSTITUTION:** Slowly add 46 mL of purified water. Shake vigorously for 5 seconds to 10 seconds immediately after adding the water.**Inactive ingredients:** banana flavor (contains propylene glycol), cherry flavor (contains acetic acid, propylene glycol and triethyl citrate), citric acid monohydrate, peppermint flavor (contains ethyl alcohol and water), powdered cellulose, sucrose and xanthan gum with methylparaben sodium 0.1%, propylparaben sodium 0.02% and sodium benzoate 0.1% added as preservatives.

Store dry powder and reconstituted suspension at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Suspension: Protect from freezing. Discard unused reconstituted suspension after 30 days. Dispense in a USP tight, light-resistant container.


**KEEP CONTAINER TIGHTLY CLOSED.****Keep out of reach of children.**Discard after   /  /  

Distributed by:

**Aurobindo Pharma USA, Inc.**  
279 Princeton-Hightstown Road  
East Windsor, NJ 08520

Made in India

Code: TS/DRUGS/19/1993



P1435237

\*GTIN, Serial Number, Expiry Date and LOT in  
human readable along with 2D Data Matrix shall  
be printed during packing.**Coding Area**

(45 x 20 mm)

Dotted lines not to be printed

**FAMOTIDINE**

famotidine powder, for suspension

**Product Information**

|                                |                         |                           |               |
|--------------------------------|-------------------------|---------------------------|---------------|
| <b>Product Type</b>            | HUMAN PRESCRIPTION DRUG | <b>Item Code (Source)</b> | NDC:59651-701 |
| <b>Route of Administration</b> | ORAL                    |                           |               |

**Active Ingredient/Active Moiety**

| <b>Ingredient Name</b>                                       | <b>Basis of Strength</b> | <b>Strength</b> |
|--|--------------------------|-----------------|
| FAMOTIDINE (UNII: 5QZO15J2Z8) (FAMOTIDINE - UNII:5QZO15J2Z8) | FAMOTIDINE               | 40 mg in 5 mL   |

**Inactive Ingredients**

| <b>Ingredient Name</b>                     | <b>Strength</b> |
|--|-----------------|
| PROPYLENE GLYCOL (UNII: 6DC9Q167V3)        |                 |
| ACETIC ACID (UNII: Q40Q9N063P)             |                 |
| TRIETHYL CITRATE (UNII: 8Z96QXD6UM)        |                 |
| CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP) |                 |
| ALCOHOL (UNII: 3K9958V90M)                 |                 |
| WATER (UNII: 059QF0KO0R)                   |                 |
| POWDERED CELLULOSE (UNII: SMD1X3X09M)      |                 |
| SUCROSE (UNII: C151H8M554)                 |                 |
| XANTHAN GUM (UNII: TTV12P4NEE)             |                 |
| METHYLPARABEN SODIUM (UNII: CR6K9C2NHK)    |                 |
| PROPYLPARABEN SODIUM (UNII: 625NNB0G9N)    |                 |
| SODIUM BENZOATE (UNII: OJ245FE5EU)         |                 |

## Product Characteristics

|                 |                            |                     |  |
|-----------------|----------------------------|---------------------|--|
| <b>Color</b>    | WHITE (White to off-white) | <b>Score</b>        |  |
| <b>Shape</b>    |                            | <b>Size</b>         |  |
| <b>Flavor</b>   | BANANA, CHERRY, PEPPERMINT | <b>Imprint Code</b> |  |
| <b>Contains</b> |                            |                     |  |

## Packaging

| # | Item Code        | Package Description                                  | Marketing Start Date | Marketing End Date |
|---|------------------|--|----------------------|--------------------|
| 1 | NDC:59651-701-50 | 50 mL in 1 BOTTLE; Type 0: Not a Combination Product | 07/09/2025           |                    |

## Marketing Information

| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
|--------------------|--|----------------------|--------------------|
| ANDA               | ANDA219091                               | 07/09/2025           |                    |

**Labeler** - Aurobindo Pharma Limited (650082092)

## Establishment

| Name                     | Address | ID/FEI    | Business Operations                          |
|--------------------------|---------|-----------|--|
| Aurobindo Pharma Limited |         | 918917642 | ANALYSIS(59651-701) , MANUFACTURE(59651-701) |

Revised: 7/2025

Aurobindo Pharma Limited